SNY formally kills the Otamixaban (oral FXa-inhibitor) program, which is not surprising. Like PTLA’s Betrixaban (which is still in development but shouldn’t be, IMO), Otamixaban was too little, too late to compete with the likes of Eliquis and Xarelto.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.